CorMedix annual gross margin
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2024
2025
CorMedix's gross margin was 88.46% for fiscal 2025.
View full CorMedix company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 88.46% | −4.20 pp |
| 2024 | 2024-12-31 | 92.66% | −1.63 pp |
| 2022 | 2022-12-31 | 94.29% | +72.30 pp |
| 2021 | 2021-12-31 | 22.00% | +7.62 pp |
| 2020 | 2020-12-31 | 14.37% | +46.13 pp |
| 2019 | 2019-12-31 | −31.76% | −39.44 pp |
| 2018 | 2018-12-31 | 7.68% | −57.41 pp |
| 2017 | 2017-12-31 | 65.09% | +128.71 pp |
| 2016 | 2016-12-31 | −63.62% | −11.94 pp |
| 2015 | 2015-12-31 | −51.68% | +83.85 pp |
| 2014 | 2014-12-31 | −135.53% | +9839.68 pp |
| 2013 | 2013-12-31 | −9,975.21% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 75.66% | −19.65 pp |
| Q1 2026 | 2026-03-31 | 82.50% | −13.42 pp |
| Q4 2025 | 2025-12-31 | 81.70% | −12.31 pp |
| Q3 2025 | 2025-09-30 | 91.66% | +54.91 pp |
| Q2 2025 | 2025-06-30 | 95.31% | −3.32 pp |
| Q1 2025 | 2025-03-31 | 95.91% | +17.46 pp |
| Q3 2024 | 2024-09-30 | 94.01% | −4.43 pp |
| Q2 2024 | 2024-06-30 | 36.75% | −43.25 pp |
| Q4 2022 | 2022-12-31 | 98.63% | +83.76 pp |
| Q3 2022 | 2022-09-30 | 78.45% | +44.52 pp |
| Q2 2022 | 2022-06-30 | 98.44% | +174.56 pp |
| Q1 2022 | 2022-03-31 | 80.00% | +49.50 pp |
| Q4 2021 | 2021-12-31 | 14.88% | +17.60 pp |
| Q3 2021 | 2021-09-30 | 33.93% | +19.84 pp |
| Q2 2021 | 2021-06-30 | −76.12% | −59.45 pp |
| Q1 2021 | 2021-03-31 | 30.50% | −3.98 pp |
| Q4 2020 | 2020-12-31 | −2.72% | +83.43 pp |
| Q3 2020 | 2020-09-30 | 14.09% | +46.84 pp |
| Q2 2020 | 2020-06-30 | −16.67% | −56.76 pp |
| Q1 2020 | 2020-03-31 | 34.48% | +73.13 pp |
| Q4 2019 | 2019-12-31 | −86.15% | −102.77 pp |
| Q3 2019 | 2019-09-30 | −32.75% | −48.88 pp |
| Q2 2019 | 2019-06-30 | 40.09% | +385.90 pp |
| Q1 2019 | 2019-03-31 | −38.65% | −15.53 pp |
| Q4 2018 | 2018-12-31 | 16.62% | −151.81 pp |
| Q3 2018 | 2018-09-30 | 16.13% | +25.26 pp |
| Q2 2018 | 2018-06-30 | −345.81% | −432.55 pp |
| Q1 2018 | 2018-03-31 | −23.12% | +113.42 pp |
| Q4 2017 | 2017-12-31 | 168.43% | +138.53 pp |
| Q3 2017 | 2017-09-30 | −9.13% | −10.32 pp |
| Q2 2017 | 2017-06-30 | 86.74% | +1120.48 pp |
| Q1 2017 | 2017-03-31 | −136.54% | −115.29 pp |
| Q4 2016 | 2016-12-31 | 29.89% | +645.51 pp |
| Q3 2016 | 2016-09-30 | 1.19% | −0.34 pp |
| Q2 2016 | 2016-06-30 | −1,033.74% | −1048.89 pp |
| Q1 2016 | 2016-03-31 | −21.25% | −65.85 pp |
| Q4 2015 | 2015-12-31 | −615.61% | −393.33 pp |
| Q3 2015 | 2015-09-30 | 1.53% | −28.53 pp |
| Q2 2015 | 2015-06-30 | 15.15% | +52.28 pp |
| Q1 2015 | 2015-03-31 | 44.60% | +608.59 pp |
| Q4 2014 | 2014-12-31 | −222.28% | +9752.93 pp |
| Q3 2014 | 2014-09-30 | 30.06% | — |
| Q2 2014 | 2014-06-30 | −37.13% | — |
| Q1 2014 | 2014-03-31 | −563.98% | — |
| Q4 2013 | 2013-12-31 | −9,975.21% | — |
Over the last five reported fiscal years, CorMedix's gross margin increased from −31.76% to 88.46%, a change of +120.22 percentage points. The latest reported quarter, Q2 2026, shows 75.66%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CorMedix filings at SEC.gov ↗